In CRC, analysis of cell lines and biopsy tissue from patients with tumors previously wild-type for KRAS mutations has shown that cetuximab treatment results in the emergence of KRAS-mutated sub-clones, as detected by analyzing circulating tumor DNA (ctDNA)11. Here, KRAS is linked to colorectal carcinoma.